Analysts Set Nuvation Bio Inc. (NYSE:NUVB) PT at $7.83 (2025)

Posted by Defense World Staff on Apr 26th, 2025

Nuvation Bio Inc. (NYSE:NUVB – Get Free Report) has been given a consensus recommendation of “Buy” by the six brokerages that are presently covering the stock, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $7.83.

Several equities research analysts recently issued reports on the stock. Jones Trading assumed coverage on shares of Nuvation Bio in a report on Wednesday, March 12th. They issued a “buy” rating and a $10.00 target price for the company. JMP Securities started coverage on shares of Nuvation Bio in a report on Wednesday. They issued a “market outperform” rating and a $6.00 target price for the company. Royal Bank of Canada restated an “outperform” rating and issued a $10.00 price objective (up from $6.00) on shares of Nuvation Bio in a research report on Tuesday, January 7th. Citigroup assumed coverage on Nuvation Bio in a report on Wednesday. They issued an “outperform” rating on the stock. Finally, Citizens Jmp began coverage on shares of Nuvation Bio in a report on Wednesday. They issued a “mkt outperform” rating and a $6.00 target price on the stock.

Check Out Our Latest Analysis on Nuvation Bio

Nuvation Bio Price Performance

NUVB opened at $2.13 on Wednesday. Nuvation Bio has a twelve month low of $1.54 and a twelve month high of $3.97. The firm has a 50 day moving average price of $1.95 and a 200-day moving average price of $2.37. The stock has a market capitalization of $721.39 million, a price-to-earnings ratio of -0.98 and a beta of 1.47.

Insider Buying and Selling at Nuvation Bio

In related news, CEO David Hung bought 200,000 shares of the company’s stock in a transaction on Friday, April 4th. The shares were acquired at an average cost of $1.66 per share, for a total transaction of $332,000.00. Following the purchase, the chief executive officer now directly owns 58,481,054 shares of the company’s stock, valued at approximately $97,078,549.64. The trade was a 0.34 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 29.93% of the stock is currently owned by corporate insiders.

Institutional Trading of Nuvation Bio

A number of hedge funds have recently added to or reduced their stakes in NUVB. State Street Corp boosted its stake in shares of Nuvation Bio by 4.8% during the third quarter. State Street Corp now owns 4,166,441 shares of the company’s stock valued at $9,541,000 after purchasing an additional 191,031 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Nuvation Bio by 5.1% during the 3rd quarter. Geode Capital Management LLC now owns 4,028,692 shares of the company’s stock worth $9,227,000 after purchasing an additional 196,247 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Nuvation Bio by 479.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 442,913 shares of the company’s stock worth $1,014,000 after purchasing an additional 366,429 shares during the last quarter. Peapod Lane Capital LLC bought a new stake in Nuvation Bio during the fourth quarter valued at about $1,042,000. Finally, Palumbo Wealth Management LLC grew its stake in Nuvation Bio by 297.4% in the fourth quarter. Palumbo Wealth Management LLC now owns 65,360 shares of the company’s stock valued at $174,000 after purchasing an additional 48,914 shares during the last quarter. 61.67% of the stock is owned by hedge funds and other institutional investors.

About Nuvation Bio

(Get Free Report

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.

Featured Articles

Receive News & Ratings for Nuvation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvation Bio and related companies with MarketBeat.com's FREE daily email newsletter.